Search results
Author(s):
Shunsuke Kiuchi
,
Shinji Hisatake
,
Yoshiki Murakami
,
et al
Added:
11 months ago
The Next Frontier in Amyloidosis Management
Video Series
Author(s):
Brian Lindman
Added:
3 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in…
View more
Author(s):
Deesha Patel
,
Makrina D Savvidou
Added:
1 year ago
Author(s):
Valentina O Puntmann
,
Anastasia Shchendrygina
,
Carlos Rodriguez Bolanos
,
et al
Added:
1 year ago
Author(s):
Marianna Fontana
Added:
7 months ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single…
View more
Carol J. Whelan
Research Area(s) / Expertise:
Job title: Consultant Cardiologist, National Amyloidosis Centre & Royal Free London Hospital, University College London, UK
Author
Thibaud Damy
Author
Author(s):
Diana Hui Ping Foo
Added:
2 months ago
ESC HF 25 - Findings from Heart2Miss suggest a hub-and-spoke model for early heart failure detection can detect patients with pre-HF and HF who were previously undiagnosed, can reduce tertiary center overload and improve novice performance.Dr Diana Foo (Sarawak General Hospital, Kuching, MY) discusses the findings from the Heart2Miss study, investigating a decentralised, community-based, rapid,…
View more
Author(s):
Christophe Leclercq
Added:
3 months ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire…
View more